©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2016; 7(20): 599-604
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.599
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.599
Place of technosphere inhaled insulin in treatment of diabetes
Nasser Mikhail, Department of Medicine, OliveView-UCLA Medical Center, Sylmar, CA 91342, United States
Author contributions: Mikhail N solely contributed to this paper.
Conflict-of-interest statement: The author has no conflict of interest to declare.
Correspondence to: Nasser Mikhail, MD, Department of Medicine, OliveView-UCLA Medical Center, 14445 Olive View Dr, Sylmar, CA 91342, United States. nmikhail@dhs.lacounty.gov
Telephone: +1-818-3643205 Fax: +1-818-3644573
Received: July 19, 2016
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 20, 2016
Accepted: October 17, 2016
Article in press: October 18, 2016
Published online: December 15, 2016
Processing time: 143 Days and 6.8 Hours
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 20, 2016
Accepted: October 17, 2016
Article in press: October 18, 2016
Published online: December 15, 2016
Processing time: 143 Days and 6.8 Hours
Core Tip
Core tip: Technosphere insulin is the only approved form of inhaled insulin. It is a short-acting insulin that can be taken with meals in patients with type 1 or type 2 diabetes. In this minireview, the author provides an appraisal of this new formulation of insulin to help determine its place in the management of diabetes.